This ECTRIMS podcast episode is supported by an educational grant from Alexion, AstraZeneca Rare Diseases. Bristol Myers Squibb, Novartis, Roche, Sanofi, and UCB. Educational grant providers have no input into the podcast series content.

🎙️ What does the future hold for people living with NMOSD and MOGAD? With new treatments emerging and research advancing, there are important reasons for hope.

As part of Patient Community Day 2026, we're pleased to share the second episode in our two-part ECTRIMS Podcast series, exploring the latest research and the perspectives of people living with MS and related neurological conditions.

Host Brett Drummond sits down with Taylor Ann Macy, Director of Patient Engagement at the Sumaira Foundation who lives with NMOSD, and Dr Eoin Flanagan, Professor of Neurology at Mayo Clinic, for a conversation about scientific progress, lived experience and the importance of bringing patients and researchers together.

• What are the challenges of living with a rare neuroimmune condition?
• How are new treatments changing the outlook for NMOSD and MOGAD?
• And why are patient voices and community connections so important in shaping future research?

From the isolation that can come with a rare diagnosis to the growing optimism around treatment and research, this conversation highlights both the challenges and the possibilities ahead.

This ECTRIMS podcast episode is supported by an educational grant from Alexion, AstraZeneca Rare Diseases. Bristol Myers Squibb, Novartis, Roche, Sanofi, and UCB. Educational grant providers have no input into the podcast series content.

What does the MS community need from research – and how can we make sure the voices of people living with MS help shape what comes next?

As part of Patient Community Day 2026, we're sharing a special collaborative episode from RealTalk MS and the ECTRIMS Podcast, hosted by Jon Strum.

Jon is joined by Karen Jacoby, MS advocate and person living with MS, and Peter Feys, Professor of Rehabilitation Sciences and Neurorehabilitation at Hasselt University – for a conversation that puts the patient perspective at the centre – exploring the relationship between research, lived experience and the priorities that matter to people affected by MS.

Recorded at Patient Community Day in Toronto, the episode forms part of the wider conversations taking place during the 10th Joint ACTRIMS-ECTRIMS Meeting – but this one is specifically for, and about, the MS community.

This episode was produced and hosted by RealTalk MS – a Supporting Partner of Patient Community Day – and is being shared across ECTRIMS channels with permission from Jon Strum to help the conversation reach as many people as possible.

This ECTRIMS podcast episode is supported by an educational grant from Alexion, AstraZeneca Rare Diseases. Bristol Myers Squibb, Novartis, Roche, Sanofi, and UCB. Educational grant providers have no input into the podcast series content.